RxDoctor Payments Data

Scott McRae, MD

Gastroenterology · Cheyenne, WYNPI 1144390006

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 30.7% of the total.

$1,925in general payments, 2019–2025

Across 96 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$591
  • Gilead$238
  • Regeneron Healthcare Solutions, Inc.$154
  • Johnson & Johnson$150
  • Takeda Pharmaceuticals U.S.A., Inc.$149
  • Laborie Medical Technologies Corp.$116
  • plus $526 from 15 others

What the payments were for

  • Food & beverage$1,82095%
  • Education$613%
  • Gifts$442%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few gastroenterology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$147,869
Medicare patients
558
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcalivaObeticholic Acid12$116,533
Humira(Cf) PenAdalimumab14$97,713
CreonLipase/Protease/Amylase19$60,642
LinzessLinaclotide34$18,946
Mesalamine26$12,587
MovantikNaloxegol Oxalate12$5,309
PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C27$3,785
Ursodiol15$3,740
Omeprazole125$2,294
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag14$1,730
Pantoprazole Sodium146$1,365
Esomeprazole Magnesium12$939
Dicyclomine Hcl30$652
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl36$606
Ondansetron Hcl52$535

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Intercept Pharmaceuticals, Inc.Ocaliva$58$116,53312 claims
AbbVieCreon, Linzess$591$79,58853 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu$18$3,78527 claims
Braintree Laboratories, Inc.Suflave$55$1,73014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few gastroenterology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other gastroenterology in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →